February 5, 2026·Kristofer Prepelica, PhD

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer

This item links to coverage published on an external site.